ADVERSE EVENTS OF INTERFERONS WITH SYSTEMIC EFFECT

QR Code

ADVERSE EVENTS OF INTERFERONS WITH SYSTEMIC EFFECT

Objective: To explore the profile of adverse events associated with interferon therapy. Design: Systematic review. Data sources: Electronic and paper records in subject area from 2000 to 2014. Methods: We searched for the studies on safety and tolerability containing adverse events of interferons wi...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. A. Toporov, A. S. Kolbin
Format:	Article
Language:	Russian
Published:	Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2018-02-01
Series:	Безопасность и риск фармакотерапии
Subjects:	нежелательные явления интерфероны фармаконадзор adverse event pharmacovigilance interferon side effect
Online Access:	https://www.risksafety.ru/jour/article/view/10
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Problems of interchangeability of systemic interferons for treatment of multiple sclerosis
by: I. I. Snegireva, et al.
Published: (2018-02-01)

Modern methods of identification of adverse events associated with medication errors
by: A. P. Pereverzev, et al.
Published: (2018-02-01)

Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer
by: M. E. Cabanillas, et al.
Published: (2020-02-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

Commentary: Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)
by: Matthew Warren Brunke, et al.
Published: (2025-07-01)

Comparative Analysis of Adverse Effects: Protein Kinase Inhibitors Versus Traditional Anticancer Therapies
by: Ioana Lavinia Radulian, et al.
Published: (2025-04-01)

A real-world pharmacovigilance study of lorazepam based on the FDA adverse event reporting system database
by: Chunyue Fang, et al.
Published: (2025-06-01)

Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system
by: Qian Yu, et al.
Published: (2025-08-01)

Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database
by: Juan Su, et al.
Published: (2025-07-01)

DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines
by: Matthew Halma, et al.
Published: (2025-03-01)

Safety of creatine supplementation: Analysis of Adverse Events reported in clinical trials and adverse event reports
by: Sarah E. Johnson, et al.
Published: (2025-09-01)

SAFETY OF BIOLOGICAL PREPARATIONS AND SMALL MOLECULES. ARE THERE ANY DIFFERENCES?
by: A. S. Kolbin, et al.
Published: (2013-05-01)

Modern approaches to collecting and reporting information on side effects
by: K. E. Zatolochina, et al.
Published: (2018-02-01)

Disproportionality analysis and risk factor assessment of drug-associated thyroid dysfunction adverse events: a study based on the FAERS database
by: Zhifang Wang, et al.
Published: (2025-07-01)

Psychiatric safety associated with hormone replacement therapy for menopausal symptoms: a real-world study of the FDA adverse event reporting system
by: Nan Chen, et al.
Published: (2025-06-01)

Optimisation of Approaches to Adverse Event Analysis in Bioequivalence Clinical Trials
by: A. B. Verveda, et al.
Published: (2024-04-01)

Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
by: Hilal A. Thaibah, et al.
Published: (2025-06-01)

Spontaneous Adverse Drug Reaction Reporting of Congenital Malformations: A Danish National Register Study
by: Ulrik Lausten-Thomsen, et al.
Published: (2025-06-01)

Pharmacovigilance and signal detection of adverse drug events associated with proteasome inhibitors in multiple myeloma: a real-world analysis using the FAERS database
by: JunYun Luo, et al.
Published: (2025-12-01)

Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER
by: Xiaomeng Di, et al.
Published: (2025-07-01)

Interferon Gamma and Tumor Necrosis Factor Alpha Are Inflammatory Biomarkers for Major Adverse Cardiovascular Events in Patients with Peripheral Artery Disease
by: Ben Li, et al.
Published: (2025-06-01)

PHARMACOEPIDEMIOLOGICAL STUDIES OF ADVERSE REACTIONS OF DEVELOPED DRUGS
by: E. J. Kolesnikova
Published: (2022-06-01)

Adverse Events Following Vaccination: A Review of Russian and International Terminology
by: A. S. Korovkin, et al.
Published: (2024-04-01)

SUGGESTIONS FOR PREVENTING UNDESIRED REACTIONS AT APPLICATION IMMUNOBIOLOGICAL MEDICINAL PRODUCTS IN THE RUSSIAN FEDERATION
by: N. A. Ozeretskovsky, et al.
Published: (2018-02-01)

Офтальмоферон® при заболеваниях глаз у детей. Обзор литературы и собственные наблюдения
Published: (2014-07-01)

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
by: Zhenpo Zhang, et al.
Published: (2025-07-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

DRUG SAFETY MONITORING SERVICE IN DEVELOPING ORGANIZATIONS / MANUFACTURERS OF DRUGS FOR VETERINARY USE
by: N. P. Biryukova, et al.
Published: (2019-09-01)

The risk management system as the important part of good pharmacovigilance practices (GVP)
by: A. S. Kazakov, et al.
Published: (2018-02-01)

Interferon Beta: Analysis of Information on Adverse Reactions and Evaluation of Possibility of Signal Identification
by: K. E. Zatolochina, et al.
Published: (2019-06-01)

Guidelines for the planning and implementation of pharmacovigilance systems audit
by: S. V. Glagolev, et al.
Published: (2018-02-01)

Estimation of Possible Use of Interferon Inductors for Prevention of Postvaccional Reactions to TEOVac in Animal Models
by: N. K. Chernikova, et al.
Published: (2020-05-01)

COMPARATIVE REVIEW OF METHODOLOGIES FOR ESTIMATING THE COST OF ADVERSE DRUG REACTIONS IN THE RUSSIAN FEDERATION AND BRAZIL
by: G. I. Syraeva, et al.
Published: (2021-03-01)

Age-stratified pharmacovigilance of azithromycin: a multimethod signal detection analysis in the FAERS database
by: Zhenpo Zhang, et al.
Published: (2025-12-01)

Evaluating Triptan Safety in Pediatric Migraine Management: A Comprehensive Pharmacovigilance Analysis
by: Chen J, et al.
Published: (2025-06-01)

Evaluation of the effectiveness of antiviral therapy for coronavirus infection (COVID-19) with the inclusion of recombinant interferon alpha-2b
by: A. V. Mordyk, et al.
Published: (2022-10-01)

Structure of Adverse Events Following Immunisation against Coronavirus Infection (COVID-19) in the Kyrgyz Republic
by: A. A. Zurdinova, et al.
Published: (2022-12-01)

Adverse Reactions of Drugs Containing Valeriana and Corvalol: Analysis of Spontaneous Reporting
by: S. L. Morokhina, et al.
Published: (2018-12-01)

Possible Association Between Concomitant Use of SSRIs with NSAIDs and an Increased Risk of Adverse Events Among People with Depressive Disorders: Data Mining of FDA Adverse Event Reporting System
by: Yi Zhang, et al.
Published: (2025-07-01)

ADVERSE EFFECTS OF LONG-TERM CORTICOSTEROID THERAPY OF NEPHROTIC SYNDROME IN CHILDREN
by: T. L. Nastausheva, et al.
Published: (2017-08-01)